## Marina Panova-Noeva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8213041/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiovascular profiling in the diabetic continuum: results from the population-based Gutenberg Health Study. Clinical Research in Cardiology, 2022, 111, 272-283.	3.3	11
2	Variation of platelet function in clinical phenotypes of acute venous thromboembolism – Results from the GMPâ€VTE project. Journal of Thrombosis and Haemostasis, 2022, 20, 705-715.	3.8	3
3	Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background. Thrombosis Journal, 2022, 20, .	2.1	2
4	Rationale, design and baseline characteristics of the MyoVasc study: A prospective cohort study investigating development and progression of heart failure. European Journal of Preventive Cardiology, 2021, 28, 1009-1018.	1.8	10
5	Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample. Thrombosis and Haemostasis, 2021, 121, 174-181.	3.4	5
6	Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. Scientific Reports, 2021, 11, 2577.	3.3	4
7	Promotion of Arterial Stiffness by Childhood Cancer and Its Characteristics in Adult Longâ€Term Survivors. Journal of the American Heart Association, 2021, 10, e015609.	3.7	8
8	Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. Blood, 2021, 137, 2681-2693.	1.4	11
9	Cigarette Smoking Is Related to Endothelial Dysfunction of Resistance, but Not Conduit Arteries in the General Population—Results From the Gutenberg Health Study. Frontiers in Cardiovascular Medicine, 2021, 8, 674622.	2.4	16
10	The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. ESC Heart Failure, 2021, 8, 2991-3001.	3.1	20
11	Sex-Specific Relationship Between Parathyroid Hormone and Platelet Indices in Phenotypes of Heart Failure—Results From the MyoVasc Study. Frontiers in Cardiovascular Medicine, 2021, 8, 682521.	2.4	3
12	A targeted proteomics investigation of the obesity paradox in venous thromboembolism. Blood Advances, 2021, 5, 2909-2918.	5.2	3
13	Chronic venous insufficiency, cardiovascular disease, and mortality: a population study. European Heart Journal, 2021, 42, 4157-4165.	2.2	37
14	Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets. Journal of Clinical Medicine, 2020, 9, 92.	2.4	16
15	The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, 271-279.	3.0	3
16	Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study. Haematologica, 2020, 105, 2327-2334.	3.5	33
17	Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study. Journal of Clinical Medicine, 2020, 9, 3281. 	2.4	2
18	Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism – results from clinical observation studies. EBioMedicine, 2020, 60, 102978.	6.1	22

MARINA PANOVA-NOEVA

#	Article	IF	CITATIONS
19	Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients. Journal of Clinical Medicine, 2020, 9, 2892.	2.4	1
20	Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency. Journal of Clinical Medicine, 2020, 9, 645.	2.4	2
21	Isolated Pulmonary Embolism Is Associated With a High Risk of Arterial Thrombotic Disease. Chest, 2020, 158, 341-349.	0.8	11
22	Missing value imputation in proximity extension assay-based targeted proteomics data. PLoS ONE, 2020, 15, e0243487.	2.5	5
23	Abstract 13812: Pulmonary Function Predicts Cardiac Function, Structure & Clinical Outcome in Chronic Heart Failure: Results From the Myovasc Study. Circulation, 2020, 142, .	1.6	Ο
24	A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE). Thrombosis Research, 2019, 181, 84-91.	1.7	14
25	Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service. Thrombosis and Haemostasis, 2019, 119, 1347-1357.	3.4	8
26	The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism. Haematologica, 2019, 104, e424-e427.	3.5	8
27	Prevalence of mental distress among adult survivors of childhood cancer in Germany—Compared to the general population. Cancer Medicine, 2019, 8, 1865-1874.	2.8	31
28	Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in Thrombotic Disease. Hamostaseologie, 2019, 39, 152-163.	1.9	8
29	Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample. Scientific Reports, 2019, 9, 20090.	3.3	Ο
30	Rivaroxaban Effects Illustrate the Underestimated Importance of Activated Platelets in Thrombin Generation Assessed by Calibrated Automated Thrombography. Journal of Clinical Medicine, 2019, 8, 1990.	2.4	10
31	Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism. Clinical Research in Cardiology, 2019, 108, 787-796.	3.3	5
32	Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists. Journal of the American Geriatrics Society, 2019, 67, 463-470.	2.6	13
33	Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. Clinical Research in Cardiology, 2019, 108, 438-447.	3.3	6
34	1.4 Prognostic Relevance of Augmentation Index in Prevalent Cardiovascular Disease and Total Mortality: Data From the General Population. Artery Research, 2019, 25, S3-S3.	0.6	0
35	Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets—Results from the Gutenberg Health Study. Thrombosis and Haemostasis, 2018, 118, 873-882. 	3.4	11
36	Coagulation and inflammation in longâ€ŧerm cancer survivors: results from the adult population. Journal of Thrombosis and Haemostasis, 2018, 16, 699-708.	3.8	22

Marina Panova-Noeva

#	Article	IF	CITATIONS
37	Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. European Heart Journal, 2018, 39, 1555-1562.	2.2	79
38	1.1 PROMOTION OF ARTERIAL STIFFNESS BY CHILDHOOD CANCER AND ITS CHARACTERISTICS IN ADULT LONG-TERM SURVIVORS. Artery Research, 2018, 24, 67.	0.6	0
39	Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. Clinical Research in Cardiology, 2018, 107, 1170-1179.	3.3	7
40	Abstract 147: The Role of Thrombin Generation in Cardiovascular Disease and Mortality - Results from the Population-based Gutenberg Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	0
41	Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample. Blood, 2018, 132, 1169-1169.	1.4	О
42	Mean Platelet Volume and Arterial Stiffness – Clinical Relationship and Common Genetic Variability. Scientific Reports, 2017, 7, 40229.	3.3	17
43	Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis. Scientific Reports, 2017, 7, 4591.	3.3	26
44	Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study. Blood, 2016, 127, 251-259.	1.4	54
45	Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes. Diabetes Care, 2015, 38, 1356-1364.	8.6	177
46	Phospholipidâ€dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. American Journal of Hematology, 2014, 89, 68-73.	4.1	53
47	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thrombosis Research, 2013, 132, 88-93.	1.7	41
48	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood, 2011, 118, 2599-2601.	1.4	61
49	Plateletâ€induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. American Journal of Hematology, 2011, 86, 337-342.	4.1	78
50	Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2010, 104, 151-156.	3.4	51
51	Treatment of thromboembolism in cancer patients. Expert Opinion on Pharmacotherapy, 2010, 11, 2049-2058.	1.8	8
52	ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients. Blood, 2010, 116, 1981-1981.	1.4	2
53	Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia. Blood, 2010, 116, 1985-1985.	1.4	1
54	Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?. Thrombosis and Haemostasis, 2009, 101, 1156-1162.	3.4	83

#	Article	IF	CITATIONS
55	Procoagulant mechanisms in tumour cells. Best Practice and Research in Clinical Haematology, 2009, 22, 49-60.	1.7	146
56	Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. Thrombosis and Haemostasis, 2009, 101, 1156-62.	3.4	23
57	Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV). Blood, 2008, 112, 3736-3736.	1.4	0